COVID-19 vaccine - Avimex
Alternative Names: AVX/COVID-12 (Patria) Vaccine; AVX/COVID-12 vaccine; Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine; Patria; Recombinant NDV Vectored Vaccine for SARS-CoV-2; Recombinant NDV Vectored Vaccine for SARS-CoV-2 - Avimex; Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2; Recombinant SARS-CoV-2 vaccine - Avimex; Sars-CoV-2 vaccine - AvimexLatest Information Update: 11 Aug 2023
At a glance
- Originator Avimex
- Developer Avimex; National Institute of Respiratory Diseases (INER, in Spanish)
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 24 Jul 2023 Avimex completes a phase II trial in COVID-2019 infections (Prevention) in Mexico (Intranasal) (IM) (NCT05205746)
- 30 Sep 2022 Avimex completes a phase-I trial in COVID-2019 infections (Prevention) in Mexico (IM) (NCT04871737)
- 30 Sep 2022 Avimex completes a phase-I trial in COVID-2019 infections (Prevention) in Mexico (Intranasal) (NCT04871737)